On October 30, Gelonhui announced that North China Pharmaceutical (600812.SH) disclosed that its subsidiary received a total of RMB 1.5584 million in government grants related to revenue from July 24, 2024, to the date of this announcement, accounting for 31.87% of the net income attributable to the shareholders of the listed company in 2023.
华北制药(600812.SH)：下属子公司获得政府补助
north china pharmaceutical (600812.SH): Subsidiary company received government subsidies
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated